Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits
Wednesday, July 15, 2009 - 08:07
in Health & Medicine
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.